Harvard’s Aaron Kesselheim resigns from expert panel in wake of aducanumab OK, blasting FDA for ‘worst drug approval decision in recent U.S. history'

Max Gelman

Senior Editor

A third member of the FDA’s Peripheral and Central Nervous System Drugs Advisory Committee has resigned in the wake of Biogen’s controversial Aduhelm approval, slamming …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

Harvard’s Aaron Kesselheim resigns from expert panel in wake of aducanumab OK, blasting FDA for ‘worst drug approval decision in recent U.S. history'

Max Gelman

Senior Editor

Sign up to read this article for free.

'Go ahead and do it': Top RFK Jr. deputy dares drugmakers that might pull manufacturing over new price pressure

The inside story of the six-month sprint to create the first custom CRISPR therapy for one infant’s rare disease

New CBER chief Prasad is readying 'massive framework' around vaccines, Makary says

Bristol Myers CEO says America’s biopharma pole position is not guaranteed

Eli Lilly turns to South Korean RNA editing biotech for hearing loss in deal worth $1.3B

Exclusive: Drug compounder Empower was built on risky shortcuts, ex-employees and inspections allege

Har­vard’s Aaron Kessel­heim re­signs from ex­pert pan­el in wake of ad­u­canum­ab OK, blast­ing FDA for ‘worst drug ap­proval de­ci­sion in re­cent U.S. his­to­ry'

Max Gelman

Senior Editor

Sign up to read this article for free.

more like this

'Go ahead and do it': Top RFK Jr. deputy dares drug­mak­ers that might pull man­u­fac­tur­ing over new price pres­sure

The in­side sto­ry of the six-month sprint to cre­ate the first cus­tom CRISPR ther­a­py for one in­fant’s rare dis­ease

New CBER chief Prasad is ready­ing 'mas­sive frame­work' around vac­cines, Makary says

Bris­tol My­ers CEO says Amer­i­ca’s bio­phar­ma pole po­si­tion is not guar­an­teed

Eli Lil­ly turns to South Ko­re­an RNA edit­ing biotech for hear­ing loss in deal worth $1.3B

Ex­clu­sive: Drug com­pounder Em­pow­er was built on risky short­cuts, ex-em­ploy­ees and in­spec­tions al­lege

Harvard’s Aaron Kesselheim resigns from expert panel in wake of aducanumab OK, blasting FDA for ‘worst drug approval decision in recent U.S. history'

'Go ahead and do it': Top RFK Jr. deputy dares drugmakers that might pull manufacturing over new price pressure

The inside story of the six-month sprint to create the first custom CRISPR therapy for one infant’s rare disease

New CBER chief Prasad is readying 'massive framework' around vaccines, Makary says

Bristol Myers CEO says America’s biopharma pole position is not guaranteed

Eli Lilly turns to South Korean RNA editing biotech for hearing loss in deal worth $1.3B

Exclusive: Drug compounder Empower was built on risky shortcuts, ex-employees and inspections allege